3 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy Educational Intervention, Health Telemonitoring, Questionnaire Administration - Hematologic Malignancies | Phase 3 | Recruiting | City of Hope Medical Center | 380 | 2026-01-14 | 2026-08-28 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) ICP-248, Orelabrutinib - Hematologic Malignancies | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 226 | 2024-05-15 | 2025-11-21 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Pembrolizumab, Standard of Care (SOC), Lenvatinib - Solid Tumors, Hematologic Malignancies | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 3500 | 2018-08-21 | 2026-10-29 |
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Site (3)
Standard of Care (2) · Early Intervention, Educational (1) · Educational Status (1) · Methods (1) · Practice Guidelines as Topic (1) · lenvatinib (1) · olaparib (1) · orelabrutinib (1) · pembrolizumab (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · City of Hope Medical Center (1) · Merck Sharp & Dohme LLC (1)
China (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Costa Rica (1) · Czechia (1) · Denmark (1) · Estonia (1) · Finland (1)
Saro Armenian, DO, MPH (1) · Virginia Sun, PhD, RN (1)
2017 (1)